ReviewAntioxidants & redox signaling2013
Trypanosoma cruzi antioxidant enzymes as virulence factors in Chagas disease.
Review in Antioxidants & redox signaling, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 1 synthesis or guideline pooled it, 102 citations in OpenAlex.
- Relevance of Trypanothione Reductase Inhibitors onOxidative medicine and cellular longevity · 2018Pooled it
- Evaluation of the immune response against Trypanosoma cruzi cytosolic tryparedoxin peroxidase in human natural infection.Immunology · 2018Trial
- TrypPROTACs Unlocking New Therapeutic Strategies for Chagas Disease.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Towards a map of the immune system manipulation network byFrontiers in cellular and infection microbiology · 2025Review
- Differential antioxidant enzyme profiles reveal early molecular signatures of virulence inFrontiers in cellular and infection microbiology · 2025Article
- The End Justifies the Means: Chagas Disease from a Perspective of the Host-Life (Basel, Switzerland) · 2024Review
- Trypanosoma cruzi infection induces DNA double-strand breaks and activates DNA damage response pathway in host epithelial cells.Scientific reports · 2024Article
- What Do You Need to Know before Studying Chagas Disease? A Beginner's Guide.Tropical medicine and infectious disease · 2023Review
- Regulatory Functions of Hypoxia in Host-Parasite Interactions: A Focus on Enteric, Tissue, and Blood Protozoa.Microorganisms · 2023Review
- Immunopathological Mechanisms Underlying Cardiac Damage in Chagas Disease.Pathogens (Basel, Switzerland) · 2023Review
- A Review on the Immunological Response againstPathogens (Basel, Switzerland) · 2023Review
- Consumption of Galactose byPathogens (Basel, Switzerland) · 2022Article
- Crystal structure of Trypanosoma cruzi heme peroxidase and characterization of its substrate specificity and compound I intermediate.The Journal of biological chemistry · 2022Article
- Trypanosoma cruzi iron superoxide dismutases: insights from phylogenetics to chemotherapeutic target assessment.Parasites & vectors · 2022Article
- Characterization of the Neospora caninum peroxiredoxin: a novel peroxidase and antioxidant enzyme.Parasitology research · 2022Article
- Mitochondrial CaAntioxidants & redox signaling · 2022Review
- Structural New Data for Mitochondrial Peroxiredoxin FromFrontiers in cellular and infection microbiology · 2022Article
- Modulation of STAT-1, STAT-3, and STAT-6 activities in THP-1 derived macrophages infected with twoFrontiers in immunology · 2022Article
- Antioxidant defence system as a rational target for Chagas disease and Leishmaniasis chemotherapy.Memorias do Instituto Oswaldo Cruz · 2022Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
Abstract
significanceChagas disease (CD) affects several million people in Latin America and is spreading beyond its classical boundaries due to the migration of infected host and insect vectors, HIV co-infection, and blood transfusion. The current therapy is not adequate for treatment of the chronic phase of CD, and new drugs are warranted. RECENT ADVANCES: Trypanosoma cruzi is equipped with a specialized and complex network of antioxidant enzymes that are located at different subcellular compartments which defend the parasite against host oxidative assaults. Recently, strong evidence has emerged which indicates that enzyme components of the T. cruzi antioxidant network (cytosolic and mitochondrial peroxiredoxins and trypanothione synthetase) in naturally occurring strains act as a virulence factor for CD. This precept is recapitulated with the observed increased resistance of T. cruzi peroxirredoxins overexpressers to in vivo or in vitro nitroxidative stress conditions. In addition, the modulation of mitochondrial superoxide radical levels by iron superoxide dismutase (FeSODA) influences parasite programmed cell death, underscoring the role of this enzyme in parasite survival. CRITICAL ISSUES: The unraveling of the biological significance of FeSODs in T. cruzi programmed cell death in the context of chronic infection in CD is still under examination. FUTURE DIRECTIONS: The role of the antioxidant enzymes in the pathogenesis of CD, including parasite virulence and persistence, and their feasibility as pharmacological targets justifies further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.